NovelStem Reports Sharply Reduced Q1 Loss, Boosts Cash by $89K, Raises $250K Equity
NSTM sits 30% above its 52-week low of $0.008.
Summary
NovelStem International Corp. reported a significantly reduced net loss and a substantial increase in cash for Q1 2026, bolstered by a $250,000 equity raise, though it still faces going concern issues and internal control weaknesses.
Key Events · Earnings and Guidance · NSTM
-
Net Loss Significantly Narrowed
The net loss for the three months ended March 31, 2026, decreased to $55,021 from $207,216 in the same period last year, representing a substantial improvement in profitability.
-
Cash Position Boosted
Cash at the end of Q1 2026 increased to $89,850 from just $333 at December 31, 2025, providing critical liquidity for the micro-cap company.
-
Equity Capital Raise
The company received $250,000 in exchange for 2,450,980 shares of common stock from an unrelated party on March 13, 2026, providing essential working capital.
-
Operating Expenses Reduced
General and administrative expenses decreased significantly to $4,953 in Q1 2026 from $94,574 in Q1 2025, contributing to the reduced net loss.
Analysis · NSTM · Trade & Services
NovelStem International Corp. reported a significant narrowing of its net loss in Q1 2026, driven by substantial reductions in general and administrative expenses and interest costs. The company also significantly improved its cash position and raised $250,000 through an equity issuance, which is critical for its operations given its micro-cap status. Despite these improvements, the company continues to operate under a going concern warning and has identified a material weakness in its internal controls, indicating ongoing financial and operational challenges.
At the time of this filing, NSTM was trading at $0.01 on OTC in the Trade & Services sector, with a market capitalization of approximately $493.3K. The 52-week trading range was $0.01 to $0.33. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.